Loading...
•
Dec 31, 2019
Organogenesis Q4 2019 Earnings Report
Reported financial results for the fourth quarter and fiscal year 2019.
Key Takeaways
Organogenesis Holdings Inc. reported a 17% increase in net revenue for Q4 2019, reaching $74.6 million compared to $63.6 million in Q4 2018. The company's net loss decreased to $4.4 million from $9.3 million in the same period last year, and Adjusted EBITDA income was $0.8 million, a significant improvement from the $0.1 million loss in Q4 2018.
Net revenue increased by 17% to $74.6 million compared to Q4 2018.
Advanced Wound Care products revenue grew by 16% to $63.4 million.
Surgical & Sports Medicine products revenue increased by 25% to $11.3 million.
Net loss decreased to $4.4 million compared to $9.3 million in Q4 2018.
Organogenesis
Organogenesis
Organogenesis Revenue by Segment
Revenue by Segment
Advanced Wound Care Revenue
CapyFin.comSurgical & Sports Medicine Revenue
CapyFin.com Forward Guidance
The company introduced its full-year 2020 revenue guidance, projecting growth in the range of 5% to 6%.
Positive Outlook
- Targeted investments in commercial infrastructure.
- New product development.
- Line extensions.
- Clinical evidence initiatives.
- Continued success in 2020
Challenges Ahead
- Transition of PuraPly products to the high cost bundle in the outpatient setting beginning October 1, 2020.
- Incurred significant losses since inception and anticipates that it will incur substantial losses for the foreseeable future.
- Faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition.
- Rapid technological change could cause the Company’s products to become obsolete.
- Company must convince physicians that its products are safe and effective alternatives to existing treatments.
Revenue & Expenses
Visualization of income flow from segment revenue to net income